Table 2 Baseline characteristics of the first 115 subjects at inclusion in the OMEMI trial; Data presented as percentages or median values (25, 75 percentiles)

Age (y)

75 (72, 78)

Gender (male/female) (%)

73.9/26.1

Current smoker (%)

11.3

BMI (kg/m²)

25.5 (23.9, 28.1)

S-total cholesterol (mmol/L)

3.80 (3.20, 4.40)

S-LDL (mmol/L)

2.06 (1.69, 2.52)

S-HDL (mmol/L)

1.26 (1.03, 1.59)

S-triglycerides (mmol/L)

1.15 (0.88, 1.54)

Systolic blood pressure (mmHg)

135 (125, 150)

Pulse rate (bpm)

66 (60, 72)

STEMI (%)

33.9

Troponin-T (peak level) (ng/L)

735 (168, 2562)

Previous atrial fibrillation (%)

13.9

Previous myocardial infarction (n)

46 (40.0%)

Aspirin (%)

93.9

Clopidogrel (%)

40.8

Prasugrel (%)

12.1

Ticagrelor (%)

40.0

Anticoagulation (%)

16.5

Betablocker (%)

89.5

ACE-I/AT II blocker (%)

64.3

Calcium channel blocker (%)

21.7

Statin (%)

96.5

Diuretic (%)

27.8

Nitrates (%)

13.0

n-3 PUFA supplements (%)

47.3